amrn stock: Amarin Corporation plc

This article explains amrn stock — the Nasdaq ADR for Amarin Corporation plc — covering the company, Vascepa/VAZKEPA, clinical evidence, financials, regulatory and legal matters, market behavior, o...

2024-07-06 08:24:00

By Crypto Trailblazer

Article rating

4.3

116 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Amarin Corporation plc (AMRN)

amrn stock is the Nasdaq‑listed ticker for Amarin Corporation plc, a Dublin‑headquartered biopharmaceutical company best known for its prescription omega‑3 product sold as Vascepa (U.S. brand) and VAZKEPA (EU/other markets). This article provides an accessible, investor‑oriented overview of the company, its core product and clinical evidence, regulatory and legal context, financial and market information, corporate governance, analysts’ coverage, principal risks and where to find authoritative, up‑to‑date data on amrn stock.

The guide is organized to serve beginners and more informed readers alike: you will find a company profile and history, product and pipeline summaries, stock market behavior and metrics guidance, summaries of regulatory and litigation matters affecting Vascepa/VAZKEPA, and practical pointers to primary sources and market data providers. For trading or tracking US‑listed shares such as amrn stock, consider regulated venues and tools — including Bitget’s stock trading and Bitget Wallet for managing credentials — where available and compliant with your jurisdiction.

Note: numeric market and financial figures for amrn stock change frequently. For live prices, market cap, and volumes consult real‑time sources listed below.

Company profile

Amarin Corporation plc (AMRN) is a publicly traded biopharmaceutical company incorporated in Ireland and listed on the Nasdaq exchange as an American Depositary Receipt (ADR). The company focuses on developing and commercializing therapeutics for cardiovascular risk reduction, with its primary commercial product an ethyl‑esterified eicosapentaenoic acid (icosapent ethyl) marketed under the brand names Vascepa (primarily U.S.) and VAZKEPA (EU and other markets).

Key profile points:

Business activities: commercial sales of Vascepa/VAZKEPA, lifecycle clinical research, regulatory submissions and patent‑defense litigation; limited internal R&D beyond Vascepa’s indications and related formulations.
Founding and history: the company traces its roots to the mid‑1990s pharmaceutical ventures and restructured into Amarin Corporation plc as it pursued omega‑3 prescription development; corporate history includes multiple name and structure changes as part of international corporate strategy.
Headquarters: Dublin, Ireland (principal corporate jurisdiction); significant commercial presence and operations in the United States.
Management: Amarin’s executive leadership is led by the CEO and a senior management team responsible for commercial, clinical, and regulatory strategy. For current executive names and board composition consult the company’s investor relations materials and proxy statements.
Product lines and footprint: primary commercial focus is on Vascepa/VAZKEPA for cardiovascular risk reduction; distribution and regulatory approvals vary by jurisdiction, with the largest market historically being the United States.

History and corporate milestones

Amarin’s corporate pathway includes research and development milestones, clinical trial outcomes, label expansions and legal actions tied to patent protection and generic challenges. Some of the key historical milestones that shaped the company and amrn stock include:

Founding and early development: initial work on marine oil‑based pharmaceuticals and development of an icosapent ethyl formulation intended for prescription use.
Clinical development and pivotal trials: the conduct and reporting of major cardiovascular outcome trials that evaluated icosapent ethyl’s effect on residual cardiovascular risk in statin‑treated patients.
REDUCE‑IT and related evidence: the pivotal evidence base supporting Vascepa’s cardiovascular indication emerged from large randomized trials and subsequent peer‑reviewed analyses; these data underpinned regulatory approvals in several regions and materially influenced amrn stock volatility on publication and follow‑up analyses.
Commercial launch and scaling: following regulatory approvals and label indications, Amarin executed commercialization activities focused on cardiology and primary care prescribers in major markets.
Patent and litigation history: multiple patent disputes and generic challenges have been central to Amarin’s strategy to protect Vascepa’s market exclusivity. Litigation outcomes, settlements, and appeals have periodically affected amrn stock price behavior.
International approvals and re‑branding: expansions into markets outside the U.S. often used the VAZKEPA brand and were accompanied by local regulatory submissions and partner arrangements.
Corporate filings and structure: corporate relocations, ADR structuring and public market listing choices have been part of Amarin’s governance and investor communications.

(For precise dates, court rulings, and publication citations consult the company’s press releases, peer‑reviewed journals, and regulatory databases.)

Products and pipeline

Amarin’s commercial and clinical focus centers on icosapent ethyl, an ethyl ester of the omega‑3 fatty acid eicosapentaenoic acid (EPA). The product is marketed primarily as Vascepa in the U.S. and VAZKEPA in some other regions.

Vascepa / VAZKEPA (icosapent ethyl): indicated in approved jurisdictions for cardiovascular risk reduction in specific high‑risk patient populations, typically high triglyceride patients receiving statin therapy or other label‑defined groups depending on local approvals. The therapeutic rationale is reduction of residual cardiovascular risk beyond statin therapy, with evidence from large randomized controlled trials.
Clinical evidence: the company’s label claims and marketing are supported by randomized outcome data from major trials that measured cardiovascular endpoints (e.g., major adverse cardiovascular events). Peer‑reviewed publications and regulatory summaries document the trial designs, primary endpoints, and safety profiles. Publication of positive outcome data has driven clinician adoption and has been a key factor in amrn stock market reaction.
Other development programs: Amarin’s pipeline beyond icosapent ethyl is limited; the company has historically focused on life‑cycle management of Vascepa, exploring dosing, formulation, and new indications, while managing patent portfolio and regulatory obligations. Partnering and licensing arrangements have at times been used to access distribution channels or co‑development resources in specific markets.
Partner arrangements: where applicable, Amarin has pursued distribution partners, licensing, or marketing collaborations to expand geographic reach. Details of active partnerships are disclosed in company announcements and filings.

Stock market information

amrn stock trades on the Nasdaq exchange under the ticker AMRN. The listing is structured as an American Depositary Receipt (ADR) representing ordinary shares in Amarin Corporation plc. Investors and market participants track amrn stock for both company‑specific catalysts (trial readouts, regulatory actions, litigation outcomes, quarterly results) and broader market factors.

Key categories of information investors monitor for amrn stock include current share price and intraday trading, market capitalization, outstanding share count and float, 52‑week high/low, trading volume and average daily volume, institutional ownership, insider holdings, short interest, analyst ratings and price targets, as well as forthcoming clinical or regulatory milestones.

Trading data and key market metrics

Investors looking at amrn stock commonly review the following metrics. Because values change continuously, this section emphasizes definitions and where to get live data rather than fixed numbers:

Share price: current market price per ADS (American Depositary Share) as quoted on Nasdaq.
Market capitalization: calculated as current share price multiplied by total outstanding shares/ADS; a snapshot metric that changes with market price.
Float and outstanding shares: the free float (shares available for public trading) versus total issued ADS; float affects liquidity and volatility.
52‑week high / 52‑week low: range used to contextualize current price levels.
Average trading volume and daily volume: liquidity measures; lower average volumes can exacerbate price swings for amrn stock.
Beta and volatility metrics: statistical measures of how amrn stock moves relative to the broad market and its historical price dispersion.

Always source these metrics from live market data providers or the company’s filings for the most current values. Common sources include Nasdaq, major financial portals, and broker or trading platforms. For convenience, many investors also use market‑data dashboards and charting platforms to visualize historical performance.

Historical performance and notable price events

amrn stock has historically exhibited volatility tied to clinical trial publications, regulatory decisions, patent and litigation outcomes, and changes in commercial performance. Notable event categories that produced large price moves include:

Clinical readouts: publication or release of randomized trial data or post‑hoc analyses often triggered sharp price reactions in amrn stock as markets reassessed the commercial and regulatory implications.
Regulatory actions: approvals, label expansions, or adverse regulatory findings can create sustained price trends.
Patent litigation and generic challenges: rulings, settlements, or the filing of abbreviated new drug applications (ANDAs) for generic versions have historically led to spikes in trading activity and price volatility in amrn stock.
Earnings and commercial updates: quarterly revenue surprises (positive or negative) and updated guidance typically affect short‑term price movement.
Corporate actions: share issuances, ADR changes, or material corporate restructurings are examples of actions that can influence the share count and market capitalization.

Investors should review company press releases and regulatory filings for precise timelines behind major price events.

Financials and operating performance

This section summarizes the types of financial information relevant to amrn stock and where to obtain exact figures. For the most current revenue, profitability, balance sheet and cash flow data, consult the company’s quarterly (10‑Q) and annual (10‑K) filings and official investor presentations.

Revenue trends: Amarin’s revenue is predominantly derived from Vascepa/VAZKEPA sales. Revenue growth and trends reflect commercial uptake, pricing, formulary access, and geographic rollout.
Profitability: monitors include gross margin on product sales, operating income or loss, net income or loss, and earnings per share (EPS) on both GAAP and non‑GAAP bases.
Cash position and liquidity: the company’s cash, cash equivalents and short‑term investments determine runway for operations and possible investments in trials or litigation defense.
Debt profile: any outstanding debt instruments, maturities, and interest obligations affect capital structure and solvency considerations.
Reporting cadence: Amarin reports quarterly and annually per SEC rules, with periodic investor presentations and conference calls.

As of June 30, 2024, according to Amarin’s SEC filings, readers should consult the latest Form 10‑Q, Form 10‑K and the company’s investor presentations for specific numeric figures and trend details. Live financial portals and the company’s investor relations pages are the authoritative sources for up‑to‑date financial metrics.

Regulatory, legal and pricing matters

Regulatory approvals, labeling, pricing and reimbursement, and litigation are central to Amarin’s commercial prospects and to amrn stock valuation.

Regulatory interactions: approvals of Vascepa/VAZKEPA by health authorities (e.g., FDA in the U.S., EMA in Europe where applicable) define the marketed indications and labeling that drive prescribing behavior. Label language, boxed warnings, or restrictions can materially affect uptake.
Patent and litigation landscape: patent protection for composition, formulation, manufacturing processes and use patents has been defended in courts. Generic challengers seeking to market bioequivalent products lead to ANDA filings and potential litigation. Outcomes, settlements, and appeals can change exclusivity timelines and impact amrn stock.
Pricing and reimbursement: payer coverage (private insurers, Medicare/Medicaid in the U.S., national health systems elsewhere) and formulary placement influence patient access. Changes to reimbursement policy, pricing pressures, or cost‑effectiveness assessments can affect sales trajectory.
Potential impact: regulatory denials or narrower labeling, successful generic entry, or adverse litigation results could reduce future sales and influence amrn stock. Conversely, favorable approvals, expanded indications, or strong reimbursement can support revenue and market perception.

All regulatory and legal disclosures are documented in company filings and public court records; consult those primary sources for complete timelines and rulings.

Corporate governance and management

Amarin’s governance structure comprises a board of directors and executive officers responsible for corporate strategy, clinical development and commercial execution.

Board and leadership: the CEO leads day‑to‑day management supported by CFO, medical, regulatory and commercial heads. Board oversight addresses strategy, compensation and compliance.
Governance documents: charters, committee composition, codes of conduct and governance policies are available in the company’s investor relations or corporate governance packets.
Proxy statements: annual proxy statements (DEF 14A) detail director elections, executive compensation and shareholder proposals; these documents are primary references for governance and insider incentives.

Shareholders can assess governance quality by reviewing audit and compensation committee independence, director tenure and diversity, and shareholder engagement disclosures.

Analysts, ratings and sentiment

Sell‑side analysts covering amrn stock typically focus on: commercial uptake of Vascepa, the addressable market for the active ingredient in indicated populations, payer access, upcoming clinical or regulatory catalysts, and the litigation/patent timeline.

Consensus and targets: analysts publish ratings (buy/hold/sell) and price targets based on models that combine expected sales, margins, and patent longevity. Consensus sentiment changes as trial or legal outcomes evolve.
Common considerations: market size for cardiovascular risk reduction, degree of label adoption by clinicians, competition from other therapies or generics, and the outcome of pending litigation.
Retail and community sentiment: retail investor forums, social feeds and discussion boards sometimes focus on perceived short squeezes, trial outcomes, or activist interest; such sentiment can temporarily amplify volume and price moves in amrn stock but is separate from fundamental valuation.

Investors should consult published analyst notes and consensus data from mainstream financial portals while noting that analyst coverage and price targets are opinions, not guarantees.

Shareholders, ownership and short interest

Ownership structure and short interest are useful indicators for liquidity and potential price dynamics in amrn stock.

Institutional holders: large mutual funds, ETFs, and institutional investors may hold meaningful positions disclosed in 13F filings; tracking major holders provides insight into long‑term investor confidence.
Insider ownership: executive and director holdings, and scheduled insider sales or purchases, are reported in insider trading filings; significant insider buying may be viewed positively by some investors while sales may raise questions about timing.
Short interest: the proportion of shares sold short relative to float can signal market skepticism or potential short‑squeeze dynamics. High short interest often correlates with increased volatility around news events affecting amrn stock.

Regularly updated ownership snapshots and short interest data are available from market data providers and regulatory filings.

Risks

Investors considering amrn stock should account for principal risk categories. This is not exhaustive but highlights the main areas of concern:

Clinical and regulatory risk: negative trial outcomes or adverse regulatory reviews can reduce market prospects.
Competitive risk: generic entrants, alternative therapies, or new clinical evidence favoring competitor treatments could erode market share.
Commercial execution and reimbursement risk: limited payer coverage, pricing pressures, or prescribing inertia can constrain sales growth.
Litigation and patent risk: unfavorable rulings or settlements shortening exclusivity would materially affect revenue potential.
Financial and market risk: insufficient liquidity, cash burn, dilutive financing, or macroeconomic shocks may influence share price and company operations.

This section does not constitute investment advice. It is essential to consult multiple authoritative sources and the company’s risk disclosures in periodic filings before forming an investment opinion on amrn stock.

Recent developments

This article is intended as a maintained guide; specific recent developments for amrn stock should be pulled from the company’s press releases, SEC filings and reputable financial news outlets.

As of June 30, 2024, according to Amarin’s SEC filings, readers should refer to the company’s Form 10‑Q and press releases for the latest revenue and cash balance figures related to Vascepa commercialization and legal proceedings.
Clinical, regulatory and legal updates often produce immediate moves in amrn stock; readers are advised to check the latest company announcements and court dockets for up‑to‑the‑minute developments.

(Editors: update this section regularly with dated press release citations and earnings release summaries. Example phrasing: “As of [YYYY‑MM‑DD], according to [source], Amarin reported…”)

Market data sources and further reading

For real‑time quotes and historical data on amrn stock, consult primary and reputable secondary sources. Primary sources include the company’s investor relations site and SEC filings. Market and data portals commonly used by investors include Nasdaq, Yahoo Finance, TradingView, Barchart, Investing.com, YCharts and mainstream financial news outlets.

Suggested authoritative sources to check for amrn stock:

Amarin investor relations and press release archive
SEC filings (Forms 10‑Q, 10‑K, 8‑K, DEF 14A)
Peer‑reviewed clinical publications (e.g., New England Journal of Medicine, Lancet) documenting pivotal trial results
Nasdaq quotes and trade data
Market screener and charting platforms for price history and technical indicators

When trading or monitoring amrn stock, use regulated trading venues and consider Bitget’s stock trading services where available and compliant with your jurisdiction. For credential and key management, Bitget Wallet is recommended for users of Bitget’s broader product suite.

References

This guide draws on types of primary source material and commonly used market data providers. The following categories are recommended for citation and verification when expanding or updating this article on amrn stock:

Company filings and investor communications: SEC Forms 10‑K, 10‑Q, 8‑K, DEF 14A and official press releases (source: company investor relations).
Peer‑reviewed clinical trial publications and supplemental analyses (example source: major medical journals reporting on pivotal Vascepa/VAZKEPA trials).
Regulatory documents: FDA approval letters, labeling information and European regulatory summaries where applicable.
Market data portals and exchanges: Nasdaq real‑time quotes and historical data, well‑known financial data providers for market cap, float and volume.
Financial news and research: established financial media and sell‑side research reports (for sentiment and target ranges), always noting publication dates.

Editors and contributors should include full citations (title, publication, date) when adding event‑specific facts or numerical data to the amrn stock article.

Final notes and next steps

amrn stock is driven by a concentrated set of commercial and clinical factors centering on Vascepa/VAZKEPA and its regulatory and patent environment. Readers seeking to track amrn stock should combine: (1) regular checks of the company’s investor releases and SEC filings, (2) monitoring of peer‑reviewed clinical publications and regulator announcements, and (3) live market data from the sources listed above.

To explore trading or tracking US‑listed tickers like amrn stock, consider regulated platforms and tools. Learn more about Bitget’s stock trading features and Bitget Wallet for credential management where those services are available and permitted in your jurisdiction.

Actionable tip: add amrn stock to a watchlist on your preferred data platform and enable alerts for press releases and FDA or court filings to stay informed about material catalysts.

Explore more Bitget features or the company’s investor relations materials to dive deeper into specific metrics and event timelines for amrn stock.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.